接受艾代拉利司治疗的慢性淋巴细胞白血病患者的医学合并症:两项大型随机临床试验分析
该分析纳入两项随机试验中481例接受艾代拉利司治疗的慢性淋巴细胞白血病患者,使用累积疾病评定量表(CIRS)评估合并症。合并症未显著影响艾代拉利司治疗结局;在CIRS评分>6或至少一种严重合并症的患者中,艾代拉利司联合抗CD20治疗较抗CD20单药的无进展生存期和客观缓解率更优。
要点
- 合并症未显著影响艾代拉利司治疗患者的结局。
- CIRS评分>6与≤6患者的中位无进展生存期分别为16.3个月与19.1个月。
- 高合并症患者中,联合治疗较单药的中位无进展生存期分别为16.3个月与6.9个月。
核心结论
- 合并症不会预示接受艾代拉利司联合抗CD20治疗的慢性淋巴细胞白血病患者结局更差。
研究设计与样本
- 分析两项随机试验(NCT01659021和NCT01539512)中481例接受艾代拉利司治疗的慢性淋巴细胞白血病患者。
- 合并症采用累积疾病评定量表(CIRS)评估。
- 患者接受艾代拉利司联合抗CD20(利妥昔单抗或奥法木单抗;n=284)或抗CD20单药(n=197)治疗,中位年龄69岁。
主要发现
- 艾代拉利司治疗患者中,CIRS评分>6与≤6者的客观缓解率分别为79.3%与85.8%,中位无进展生存期分别为16.3个月与19.1个月,中位总生存期分别为39.8个月与49.8个月。
- 在高合并症(CIRS评分>6)患者中,艾代拉利司联合抗CD20较抗CD20单药的中位无进展生存期为16.3个月 vs 6.9个月,优势比20.1,P<0.0001。
- 在至少有一种严重合并症的患者中,艾代拉利司联合抗CD20较抗CD20单药的中位无进展生存期为16.6个月 vs 6.5个月,优势比33.2,P<0.0001。
- 在高合并症或至少一种严重合并症患者中,艾代拉利司联合抗CD20较抗CD20单药的客观缓解率更优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comorbidities influence survival in patients with chronic lymphocytic leukaemia (CLL) treated with chemo-immunotherapy or ibrutinib. While idelalisib has been studied in patients with comorbidities, their impact has not been investigated. We analysed 481 patients treated with idelalisib on two randomised trials (NCT01659021 and NCT01539512). Comorbidities were assessed using the Cumulative Illness Risk Scale (CIRS). Patients received idelalisib + anti-CD20 (rituximab or ofatumumab; n = 284) or anti-CD20 alone (n = 197). The median age was 69 years. We found that comorbidities did not significantly affect outcomes of idelalisib therapy. The objective response rate (ORR) was 79·3% versus 85·8%, the median progression-free survival (PFS) was 16·3 versus 19·1 months, and the median overall survival (OS) was 39·8 versus 49·8 months in patients treated with idelalisib who had a CIRS score of >6 versus ≤6, correspondingly. Treatment with idelalisib + anti-CD20 was associated with superior PFS and ORR when compared to anti-CD20 monotherapy in patients who had high comorbidities (CIRS score of >6) or at least one severe comorbidity (median PFS 16·3 vs. 6·9 months and 16·6 vs. 6·5 months; odds ratio 20·1 and 33·2; P < 0·0001). Thus, comorbidities do not portend inferior outcomes in patients with CLL treated with idelalisib in combination with anti-CD20 therapy.
引用
- Gordon MJ, Huang J, Chan RJ, et al. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. 2020. PMID: 32599655. doi:10.1111/bjh.16879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。